Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$1.42 +2.2%	$1.24	$0.46 ▼ $7.49	$7.43M	-0.1	10.28 million shs	75,314 shs
CYCN Cyclerion Therapeutics	$2.45 +1.9%	$2.99	$1.27 ▼ $9.47	$8.01M	1.68	58,922 shs	25,117 shs
MBIO Mustang Bio	$1.87 +10.0%	$1.66	$0.89 ▼ $21.95	$7.44M	2.22	304,064 shs	225,951 shs
VBIV VBI Vaccines		$0.23	$0.06 ▼ $1.35	$1.87M	2.18	3.66 million shs	29.90 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	+2.16%	+10.08%	+49.00%	+44.90%	-55.06%
CYCN Cyclerion Therapeutics	+1.92%	+2.34%	-25.88%	-16.23%	-21.10%
MBIO Mustang Bio	+10.00%	+27.21%	-22.73%	+65.49%	-89.48%
VBIV VBI Vaccines	0.00%	0.00%	0.00%	0.00%	+133.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	2.3284 of 5 stars	0.0	5.0	0.0	0.0	4.4	1.7	0.6
CYCN Cyclerion Therapeutics	2.8012 of 5 stars	0.0	5.0	0.0	0.0	3.8	3.3	0.6
MBIO Mustang Bio	0.3994 of 5 stars	0.0	2.0	0.0	0.0	3.1	0.0	0.6
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	17.67	N/A	N/A	$2.20 per share	0.65
CYCN Cyclerion Therapeutics	$2M	4.08	N/A	N/A	$2.57 per share	0.95
MBIO Mustang Bio	N/A	N/A	N/A	N/A	$0.66 per share	N/A
VBIV VBI Vaccines	$9.41M	0.00	N/A	N/A	$0.32 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	-$3.06M	-$0.74	N/A	∞	N/A	-89.51%	-22.63%	-20.65%	N/A
MBIO Mustang Bio	-$15.75M	-$78.00	N/A	N/A	N/A	N/A	N/A	-29.49%	N/A
VBIV VBI Vaccines	-$92.84M	N/A	0.00	N/A	N/A	-881.79%	-525.42%	-45.87%	N/A

Latest VBIV, MBIO, APM, and CYCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	MBIO Mustang Bio	N/A	-$0.19	N/A	-$0.19	N/A	N/A
8/5/2025	Q2 2025	CYCN Cyclerion Therapeutics	N/A	-$0.11	N/A	-$0.11	N/A	N/A
5/14/2025	Q1 2025	MBIO Mustang Bio	N/A	-$0.05	N/A	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
CYCN Cyclerion Therapeutics	N/A	5.03	5.03
MBIO Mustang Bio	N/A	1.30	1.34
VBIV VBI Vaccines	N/A	0.34	0.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CYCN Cyclerion Therapeutics	75.62%
MBIO Mustang Bio	9.95%
VBIV VBI Vaccines	12.26%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CYCN Cyclerion Therapeutics	34.30%
MBIO Mustang Bio	0.21%
VBIV VBI Vaccines	10.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
CYCN Cyclerion Therapeutics	30	3.34 million	2.19 million	No Data
MBIO Mustang Bio	100	4.38 million	4.37 million	Not Optionable
VBIV VBI Vaccines	22	28.68 million	25.71 million	Optionable

VBIV, MBIO, APM, and CYCN Headlines

Recent News About These Companies

Brii Biosciences buying VBI Vaccine’s hepatitis B therapy

January 24, 2025 | ncbiotech.orgN

VBI Vaccines Restructures and Acquired by K2 VBI Trust

January 3, 2025 | tipranks.com

VBI recalls PreHevbrio and winds down operations

November 20, 2024 | thepharmaletter.comT

Hepatitis B Vaccine PreHevbrio Recalled Due to Company Bankruptcy

November 19, 2024 | empr.comE

VBI Vaccines recalls hepatitis B shot as it winds down operations

November 18, 2024 | fiercepharma.comF

VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations

November 15, 2024 | businesswire.com

VBI Vaccines Inc. (VBIV): Unpacking the 80% Stock Surge During Restructuring

August 6, 2024 | bovnews.comB

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

August 6, 2024 | investorplace.com

VBI Vaccines to be delisted from Nasdaq following restructuring

August 4, 2024 | investing.com

VBI Vaccines Provides an Update on its Restructuring Proceedings

August 3, 2024 | finance.yahoo.com

VBI Vaccines secures court protection for restructuring

August 1, 2024 | investing.com

VBI craters as investors react to Hep B vaccine data

July 31, 2024 | pharmaphorum.comP

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

July 30, 2024 | stockhouse.com

VBI Vaccines Announces Results of Annual General Meeting

June 25, 2024 | businesswire.com

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

May 29, 2024 | businesswire.com

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

May 22, 2024 | businesswire.com

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

May 15, 2024 | investorplace.com

VBI Vaccines Reports First Quarter 2024 Financial Results

May 15, 2024 | businesswire.com

VBI Vaccines expands partnership with Canadian government on a vaccine platform

May 13, 2024 | plant.caP

VBI Vaccines Reports Full Year 2023 Financial Results

April 16, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIV, MBIO, APM, and CYCN Company Descriptions

Aptorum Group NASDAQ:APM

$1.42 +0.03 (+2.16%)

Closing price 08/13/2025 03:59 PM Eastern

Extended Trading

$1.41 -0.01 (-0.99%)

As of 08/13/2025 07:20 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Cyclerion Therapeutics NASDAQ:CYCN

$2.45 +0.05 (+1.92%)

Closing price 08/13/2025 03:57 PM Eastern

Extended Trading

$2.49 +0.04 (+1.80%)

As of 08/13/2025 06:40 PM Eastern

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Mustang Bio NASDAQ:MBIO

$1.87 +0.17 (+10.00%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$1.85 -0.02 (-1.07%)

As of 08/13/2025 07:54 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time